|
🐬
|
The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics
E. Karran,
M. Mercken,
B. Strooper
|
10 |
2011 |
10
🐬
|
|
🐜
|
Aβ peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease
19 auth.
C. Janus,
J. Pearson,
J. McLaurin,
P. Mathews,
Ying Jiang,
S. Schmidt,
M. Chishti,
P. Horne,
D. Heslin,
J. French,
...
H. Mount,
R. Nixon,
M. Mercken,
C. Bergeron,
C. Bergeron,
P. Fraser,
P. George-Hyslop,
P. George-Hyslop,
D. Westaway
|
10 |
2000 |
10
🐜
|
|
🐜
|
Macroautophagy—a novel β-amyloid peptide-generating pathway activated in Alzheimer's disease
17 auth.
W. H. Yu,
A. Cuervo,
Asok Kumar,
C. Peterhoff,
S. Schmidt,
Ju-Hyun Lee,
P. Mohan,
M. Mercken,
M. Farmery,
L. Tjernberg,
...
Ying Jiang,
K. Duff,
Y. Uchiyama,
J. Näslund,
P. Mathews,
A. Cataldo,
R. Nixon
|
9 |
2005 |
9
🐜
|
|
🐜
|
A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease.
17 auth.
C. Janus,
J. Pearson,
J. McLaurin,
P. Mathews,
Y. Jiang,
S. Schmidt,
M. Chishti,
P. Horne,
D. Heslin,
J. French,
...
H. Mount,
R. Nixon,
M. Mercken,
C. Bergeron,
P. Fraser,
P. S. St George-Hyslop,
D. Westaway
|
9 |
2000 |
9
🐜
|
|
🐜
|
A Cholesterol-Lowering Drug Reduces β-Amyloid Pathology in a Transgenic Mouse Model of Alzheimer's Disease
11 auth.
L. Refolo,
M. Pappolla,
J. Lafrancois,
B. Malester,
S. Schmidt,
T. Thomas-Bryant,
...
G. Tint,
Rong Wang,
M. Mercken,
S. Petanceska,
K. Duff
|
9 |
2001 |
9
🐜
|
|
🐜
|
The switch of tau protein to an Alzheimer‐like state includes the phosphorylation of two serine‐proline motifs upstream of the microtubule binding region.
10 auth.
J. Biernat,
E. Mandelkow,
C. Schröter,
B. Lichtenberg-Kraag,
B. Steiner,
B. Berling,
...
Helmut E. Meyer,
M. Mercken,
A. Vandermeeren,
M. Goedert
|
8 |
1992 |
8
🐜
|
|
🐜
|
Presenilin 1 associates with glycogen synthase kinase-3beta and its substrate tau.
11 auth.
A. Takashima,
M. Murayama,
O. Murayama,
T. Kohno,
T. Honda,
K. Yasutake,
...
N. Nihonmatsu,
M. Mercken,
H. Yamaguchi,
Shiro Sugihara,
B. Wolozin
|
8 |
1998 |
8
🐜
|
|
🐜
|
The Alzheimer’s Association external quality control program for cerebrospinal fluid biomarkers
78 auth.
N. Mattsson,
U. Andreasson,
Staffan Persson,
H. Arai,
S. Batish,
S. Bernardini,
L. Bocchio-Chiavetto,
M. Blankenstein,
M. Carrillo,
S. Chalbot,
E. Coart,
D. Chiasserini,
Neal Cutler,
Gunilla Dahlfors,
S. Duller,
...
A. Fagan,
O. Forlenza,
G. Frisoni,
D. Galasko,
D. Galimberti,
H. Hampel,
A. Handberg,
M. Heneka,
A. Z. Herskovits,
S. Herukka,
D. Holtzman,
C. Humpel,
B. Hyman,
K. Iqbal,
M. Jucker,
S. Kaeser,
E. Kaiser,
E. Kapaki,
D. Kidd,
P. Klivényi,
Cindy S. Knudsen,
M. Kummer,
J. Lui,
A. Lladó,
P. Lewczuk,
Qiao-Xin Li,
Ralph M. Martins,
C. Masters,
J. Mcauliffe,
M. Mercken,
A. Moghekar,
J. Molinuevo,
T. Montine,
W. Nowatzke,
Richard O'Brien,
M. Otto,
G. Paraskevas,
L. Parnetti,
R. Petersen,
D. Prvulovic,
Herman P.M. de Reus,
R. Rissman,
E. Scarpini,
Alessandro Stefani,
H. Soininen,
J. Schröder,
L. Shaw,
A. Skinningsrud,
Brith Skrogstad,
A. Spreer,
L. Talib,
C. Teunissen,
J. Trojanowski,
H. Tumani,
R. Umek,
B. V. Broeck,
H. Vanderstichele,
L. Vécsei,
M. Verbeek,
M. Windisch,
Jing Zhang,
H. Zetterberg,
K. Blennow
|
8 |
2011 |
8
🐜
|
|
🐜
|
Increased expression of BIN1 mediates Alzheimer genetic risk by modulating tau pathology
55 auth.
J. Chapuis,
F. Hansmannel,
Marc Gistelinck,
Anais Mounier,
C. V. Cauwenberghe,
K. V. Kolen,
F. Geller,
Y. Sottejeau,
D. Harold,
Pierre Dourlen,
B. Grenier‐Boley,
Y. Kamatani,
B. Delepine,
Florie Demiautte,
D. Zélénika,
...
N. Zommer,
N. Zommer,
M. Hamdane,
M. Hamdane,
C. Bellenguez,
J. Dartigues,
J. Hauw,
Florent Letronne,
A. Ayral,
K. Sleegers,
A. Schellens,
L. V. Broeck,
S. Engelborghs,
P. Deyn,
Rik Vandenberghe,
M. O’Donovan,
M. Owen,
J. Epelbaum,
M. Mercken,
E. Karran,
M. Bantscheff,
G. Drewes,
G. Joberty,
D. Campion,
J. Octave,
C. Berr,
M. Lathrop,
M. Lathrop,
P. Callaerts,
D. Mann,
Julie Williams,
L. Buée,
L. Buée,
I. Dewachter,
C. Broeckhoven,
P. Amouyel,
D. Moechars,
B. Dermaut,
B. Dermaut,
J. Lambert
|
8 |
2013 |
8
🐜
|
|
🐜
|
Aβ localization in abnormal endosomes: association with earliest Aβ elevations in AD and Down syndrome
10 auth.
A. Cataldo,
S. Petanceska,
Nicole B. Terio,
C. Peterhoff,
R. Durham,
M. Mercken,
...
P. Mehta,
J. Buxbaum,
V. Haroutunian,
R. Nixon
|
8 |
2004 |
8
🐜
|
|
🐜
|
Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer’s disease
17 auth.
S. Janelidze,
E. Stomrud,
Ruben Smith,
S. Palmqvist,
N. Mattsson,
D. Airey,
Nicholas K. Proctor,
Xiyun Chai,
S. Shcherbinin,
J. Sims,
...
G. Triana-Baltzer,
C. Theunis,
Randy Slemmon,
M. Mercken,
H. Kolb,
J. Dage,
O. Hansson
|
8 |
2020 |
8
🐜
|
|
🐜
|
Exposure of rat hippocampal neurons to amyloid β peptide (25–35) induces the inactivation of phosphatidyl inositol-3 kinase and the activation of tau protein kinase I/glycogen synthase kinase-3β
7 auth.
A. Takashima,
K. Noguchi,
G. Michel,
M. Mercken,
M. Hoshi,
K. Ishiguro,
...
K. Imahori
|
8 |
1996 |
8
🐜
|
